Increased gap density predicts weakness of the epithelial barrier in vivo by confocal laser endomicroscopy in indomethacin-induced enteropathy

Digestive Diseases and Sciences

Volumn 59, Issue 7, 2014, Pages 1398-1405

  Shi, Sha ^a,b   Wang, Han ^a   Gao, Hui ^b   Li, Zhen ^a   Chen, Fei Xue ^a   Zuo, Xiu Li ^a   Li, Yan Qing ^a  

^a SHANDONG UNIVERSITY   (China)

^b TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

Confocal laser endomicroscopy; Epithelial barrier; Gap density; Tight junctions; TNF

Indexed keywords

CASPASE 3; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; RABEPRAZOLE; TEPRENONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; ENTEROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; GOBLET CELL; IN VIVO STUDY; INTESTINE INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE; TIGHT JUNCTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; DITERPENES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GOBLET CELLS; INDOMETHACIN; INTESTINAL DISEASES; INTESTINAL MUCOSA; JEJUNUM; MALE; MICROSCOPY, CONFOCAL; RABEPRAZOLE; RANDOM ALLOCATION; RATS; RATS, WISTAR; TIGHT JUNCTIONS; TREATMENT OUTCOME;

EID: 84903525204     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3076-8     Document Type: Article

References (31)

1. Brooks P, Emery P, Evans J, et al. Interpreting the clinical significance of the differential inhibition of COX-1 and COX-2. Rheumatology. 1999;38:779-788.
2. Bedson J, Whitehurst T, Lewis M, et al. Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease. Br J Gen Pract. 2001;51:1001-1003. (Pubitemid 33138291)
3. Brunelli C, Amici C, Angelini M, et al. The nonsteroidal anti-inflammatory drug indomethacin activates the eIF2 alpha kinase PKR, causing a translational block in human colorectal cancer cells. Biochem J. 2012;443:379-386.
4. Brady RR, Loveridge CJ, Dunlop MG, Stark LA. c-Src dependency of NSAID-induced effects on NF-κB-mediated apoptosis in colorectal cancer cells. Carcinogenesis. 2011;32:1069-1077.
5. Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172-1178.
6. Saurin JC. Capsule endoscopy. Endoscopy. 2007;39:986-991.
7. Matsumoto T, Kudo T, Esaki M, et al. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol. 2008;43:490-496. (Pubitemid 351450993)
8. Graham DY, Opekun AR, Willingham FF, et al. Visible small intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55-59. (Pubitemid 40092944)
9. Adebayo D, Bjarnason I. Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J. 2006;82:186-191.
10. Fortun PJ, Hawkey CJ. Nonsteroidal anti-inflammatory drugs and the small intestine. Curr Opin Gastroenterol. 2007;23:134-141. (Pubitemid 46192967)
11. Watson AJ, Chu S, Sieck L, et al. Epithelial barrier function in vivo is sustained despite gaps in epithelial layers. Gastroenterology. 2005;129:902-912. (Pubitemid 41242683)
12. Kiesslich R, Goetz M, Angus EM, et al. Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy. Gastroenterology. 2007;133:1769-1778. (Pubitemid 350180813)
13. Bullen TF, Forrest S, Campbell F, et al. Characterization of epithelial cell shedding from human small intestine. Lab Invest. 2006;86:1052-1063. (Pubitemid 44423069)
14. Garrett WS, Lord GM, Punit S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell. 2007;131:33-45. (Pubitemid 47505255)
15. Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 2007;446:557-561. (Pubitemid 46514732)
16. Liu JJ, Wong K, Thiesen AL, et al. Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. Gastrointest Endosc. 2011;73:1174-1180.
17. Liu JJ, Madsen KL, Boulanger P, et al. Mind the gaps: confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease. J Clin Gastroenterol. 2011;45:240-245.
18. Liu JJ, Rudzinski JK, Mah SJ, et al. Epithelial gaps in a rodent model of inflammatory bowel disease: a quantitative validation study. Clin Transl Gastroenterol. 2011;2:e3.
19. Jobin C, Sartor RB. The IκB/NF-κB system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol. 2000;278:C451-C462. (Pubitemid 30154924)
20. Baeuerle P, Henkle T. Function and activation of NF-κB in the immune system. Annu Rev Immunol. 1994;12:141-179.
21. Barnes P, Karin M. Nuclear factor-κB, a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071. (Pubitemid 27163860)
22. Anderson JM, Van Itallie CM. Tight junctions and the molecular basis for regulation of paracellular permeability. Am J Physiol. 1995;269:G467-G475.
23. Gitter AH, Bendfeldt K, Sehmitz H, et al. Epithelial barrier defects in HT-29/B6 colonic cell monolayers induced by tumor necrosis factor-alpha. Ann N Y Acad Sci. 2000;915:193-203. (Pubitemid 32059380)
24. Ma TY, lwamoto GK, Hoa NT, et al. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol. 2004;286:367-376.
25. Marano CW, Lewis SA, Garulacan LA, et al. Tumor necrosis factor-alpha increases sodium and chloride conductance across the right junction of CACO-2 BBE, a human intestinal epithelial cell line. J Membr Biol. 1998;161:263-274. (Pubitemid 28085051)
26. Fukui A, Naito Y, Handa O, et al. Acetyl salicylic acid induces damage to intestinal epithelial cells by xidation-related modifications of ZO-1. Am J Physiol Gastrointest Liver Physiol. 2012;303:G927-G936.
27. Watson AJ, Chu S, Sieck L, et al. Epithelial barrier function in vivo is sustained despite gaps in epithelial layers. Gastroenterology. 2005;129:902-912. (Pubitemid 41242683)
28. Pozzoli C, Menozzi A, Grandi D, et al. Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine. Naunyn Schmiedebergs Arch Pharmacol. 2007;374:283-291. (Pubitemid 46089466)
29. Yoda Y, Amagase K, Kato S, et al. Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of hemeoxygenase-1. J Physiol Pharmacol. 2010;61:287-294.
30. Lim YJ, Phan TM, Dial EJ, et al. In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine. Digestion. 2012;86:171-177.
31. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1314-1322.